File(s) not publicly available

Reason: No enhanced material

Afatinib in advanced NSCLC: a profile of its use

online resource
posted on 28.03.2018 by Emma D. Deeks, Gillian M. Keating
Compliance with ethical standards

Funding: This article was made open access (CC-BY-NC) following publication, with funding for this provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Conflict of interest: E. D. Deeks and G. M. Keating are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Additional information about this Adis Drug Review can be found here.

Abstract

Afatinib [Giotrif® (EU); Gilotrif® (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases that provides an important first-line treatment option for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations (i.e. EGFRactMUT+), and an additional treatment option for squamous NSCLC that has progressed following first-line platinum-based chemotherapy. Relative to gefitinib in the first-line treatment of EGFRactMUT+ advanced lung adenocarcinoma, afatinib prolonged progression-free survival (PFS) and time to treatment failure (TTF), but not overall survival (OS). Afatinib also prolonged PFS, but not OS, versus cisplatin-based chemotherapy in this setting; however, afatinib improved OS versus chemotherapy in the subgroup of patients with deletions in exon 19. As a second-line treatment for advanced squamous NSCLC, afatinib prolonged PFS and OS compared with erlotinib, regardless of EGFR mutation status. Afatinib had a predictable and manageable tolerability profile. Access to the full article can be found here.

© Springer International Publishing AG, part of Springer Nature 2018

Funding

Boehringer Ingelheim Pharmaceuticals, Inc.

History

Exports